These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35278193)

  • 1. Brivaracetam Modulates Short-Term Synaptic Activity and Low-Frequency Spontaneous Brain Activity by Delaying Synaptic Vesicle Recycling in Two Distinct Rodent Models of Epileptic Seizures.
    Xing H; Han X; Xu S; Sun Z; Yang S
    J Mol Neurosci; 2022 May; 72(5):1058-1074. PubMed ID: 35278193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats.
    Ge YX; Lin YY; Bi QQ; Chen YJ
    Curr Neurovasc Res; 2020; 17(4):354-360. PubMed ID: 32407277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
    Arnold S; Laloyaux C; Schulz AL; Elmoufti S; Yates S; Fakhoury T
    Epilepsy Res; 2020 Oct; 166():106404. PubMed ID: 32731118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
    Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
    Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
    Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
    Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
    Ben-Menachem E; Baulac M; Hong SB; Cleveland JM; Reichel C; Schulz AL; Wagener G; Brandt C
    Epilepsy Res; 2021 Feb; 170():106526. PubMed ID: 33461041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus.
    Niquet J; Suchomelova L; Thompson K; Klitgaard H; Matagne A; Wasterlain C
    Epilepsia; 2017 Jul; 58(7):1199-1207. PubMed ID: 28597912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Brivaracetam in Persons With Epilepsy in a Real-World Setting: A Prospective, Non-Interventional Study.
    Siddiqui F; Soomro BA; Badshah M; Rehman EU; Numan A; Ikram A; Khan MWA; Ali S; Hashim H; Salam JU; Akram A; Irfan Hashmat M; Iqbal S; Zeeshan Javed M; Iqbal SZ; Maqsood A; Khan A; Maheshwary N; Khan MA
    Cureus; 2023 Dec; 15(12):e50313. PubMed ID: 38205459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
    Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
    Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brivaracetam: a novel antiepileptic drug for focal-onset seizures.
    Stephen LJ; Brodie MJ
    Ther Adv Neurol Disord; 2018; 11():1756285617742081. PubMed ID: 29399049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.
    Niespodziany I; Rigo JM; Moonen G; Matagne A; Klitgaard H; Wolff C
    Epilepsia; 2017 Nov; 58(11):e157-e161. PubMed ID: 28850675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-AP challenge reveals that early intervention with brivaracetam prevents posttraumatic epileptogenesis in rats.
    Mejia-Bautista A; Michelson HB; Sanjana A; Famuyiwa O; Goodman JH; Ling DSF
    Epilepsy Res; 2023 Oct; 196():107217. PubMed ID: 37619297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients.
    Caraballo RH; Reyes G; Chacón S; Fortini PS
    Epilepsy Behav; 2024 Jan; 150():109561. PubMed ID: 38070405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.